Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates, referred to as patient responders. The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations.

Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received fast track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs, consisting of its development candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and additional programs targeting these two critical nodes in the DNA Damage Response, or DDR, pathways.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

Position Overview:

As a Scientist in Acrivon's Target Biology Team, you will be engaged in the discovery and characterization of new drug candidates, identification and validation of predictive biomarkers, as well as the development of therapeutics currently in, or soon approaching, oncology clinical trials. The candidate will conceive, develop, optimize, perform and/or support assays for drug profiling using mammalian proteins/cell lines/tissues and patient samples. This laboratory position will be based in Watertown, MA.

Duties and Responsibilities:

• Independently develop and/or perform cancer biological studies to investigate target biology and drug mechanism of action using mammalian cells or tissues, including genetic engineering, immunoassays, and plate-based assays.
• Independently analyze and interpret experimental data, and share/present results to the functional group, project team, and organization.
• Work collaboratively in cross-functional teams locally and internationally, communicating ideas, emerging data and questions.
• Contribute to general lab duties.
• Ensure that work is conducted in a safe and compliant manner and maintain proper records in accordance with SOPs and policies, including timely documentation of studies into an electronic notebook.

Requirements and Qualifications:

• Ph. D. in Biological Sciences or in a related discipline with 0-3 years research experience or B.S./M.S. with 5 or more years of research experience; experience in cancer research is highly desirable.
• Highly qualified in mammalian tissue culture.
• Experience with common biological assays to understand the actions of a protein target or drug including immunoassays (Western blotting, flow cytometry, ELISA, immunofluorescence), plate-based assays, molecular biology (genetic engineering, PCR), microscopy.
• Excellent communication, presentation, and organizational skills, including working knowledge of Microsoft Office

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.